☆ 4.6 Letter

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

BLOOD ADVANCES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Wolfgang A. Bethge et al.

Summary: A study conducted in Germany suggests that important outcome determinants of CD19-directed CAR T-cell treatment of LBCL in the real-world setting include bridging success, CAR-T product selection, LDH levels, and the absence of prolonged neutropenia and/or severe neurotoxicity.

BLOOD (2022)

添加到收藏夹

Article Oncology

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Kai Rejeski et al.

Summary: The study demonstrates the utility of the HT score for risk-stratifying patients for infectious complications and poor survival outcomes prior to CD19 CAR-T therapy. High-risk patients may benefit from anti-infective prophylaxis and close monitoring for potential infections and relapse. Patients with high HT scores are more likely to develop severe infections, which represent a common cause of non-relapse mortality after CAR-T.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Infectious Diseases

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report

Kai Rejeski et al.

Summary: This case report emphasizes the increased risk of fatal infectious complications in patients with profound and prolonged cytopenia following CAR T-cell therapy. It describes a rare case of C. glabrata pancolitis associated with multifactorial immunosuppression. Despite succumbing to a fatal fungal infection, the use of autologous stem cell boost was able to stimulate hematopoiesis, indicating a potential therapeutic strategy for DLBCL patients with CAR T-cell associated bone marrow aplasia.

BMC INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients

Chen Tian et al.

Summary: The study compared outcomes of aggressive B-cell NHL patients treated with IEAC or BEAC regimens followed by ASCT. Results showed that the IEAC regimen was slightly more advantageous in terms of tolerability and survival compared to the BEAC regimen, but no significant differences were observed in DLBCL or MCL patients. Multivariate analysis indicated that disease staging, survival score, lactate dehydrogenase level, disease remission, and treatment regimen were associated with patient prognosis.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Biophysics

Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

Leyre Bento et al.

Summary: This retrospective multicenter study analyzed the outcomes of 140 patients with relapsed/refractory diffuse large B cell lymphoma who underwent allogeneic hematopoietic stem cell transplantation. The study found that allo-SCT is a curative option for fit patients with chemosensitive disease receiving a transplant from a young donor, but outcomes are significantly affected by factors such as pre-transplant condition assessment and post-transplant complications.

BONE MARROW TRANSPLANTATION (2021)

添加到收藏夹

Article Hematology

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski et al.

Summary: Hematotoxicity is a common adverse event in CAR T-cell therapy, with baseline thrombocytopenia and hyperferritinemia being significant predictive markers. The CAR-HEMATOTOX model can accurately predict the occurrence of severe neutropenia.

BLOOD (2021)

添加到收藏夹

Article Medicine, General & Internal

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Bijal D. Shah et al.

Summary: KTE-X19 demonstrated a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Median overall survival was not reached in responding patients, and the therapy showed a manageable safety profile. These findings suggest that KTE-X19 has the potential to provide long-term clinical benefit to these patients.

LANCET (2021)

添加到收藏夹

Article Oncology

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Medicine, General & Internal

Cytokine Storm

David C. Fajgenbaum et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

The bone marrow niche components are adversely affected in sepsis

Fan Yin et al.

MOLECULAR BIOMEDICINE (2020)

添加到收藏夹

Article Biophysics

Early and late hematologic toxicity following CD19 CAR-T cells

Shalev Fried et al.

BONE MARROW TRANSPLANTATION (2019)

添加到收藏夹

Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

添加到收藏夹

Article Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Frederick L. Locke et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Medicine, General & Internal

Aplastic Anemia

Neal S. Young

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Hematology

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy

Joshua A. Hill et al.

BLOOD (2018)

添加到收藏夹

Article Hematology

Engraftment for CD34 selected stem cell products is not compromised by cryopreservation

Ronit Reich-Slotky et al.

TRANSFUSION (2016)

添加到收藏夹

Article Hematology

Treatment of graft failure with TNI-based reconditioning and haploidentical stem cells in paediatric patients

Heiko-Manuel Teltschik et al.

BRITISH JOURNAL OF HAEMATOLOGY (2016)

添加到收藏夹

Article Cell & Tissue Engineering

Sepsis Induces Hematopoietic Stem Cell Exhaustion and Myelosuppression through Distinct Contributions of TRIF and MYD88

Huajia Zhang et al.

STEM CELL REPORTS (2016)

添加到收藏夹

Article Hematology

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma

Timothy S. Fenske et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)

添加到收藏夹

Article Biophysics

Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma

K. Kamezaki et al.

BONE MARROW TRANSPLANTATION (2007)

添加到收藏夹

Review Biophysics

Mini-review - Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation

SN Wolff

BONE MARROW TRANSPLANTATION (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.